Metformin, a drug widely used to treat type 2 diabetes mellitus, has been shown to activate AMPK in the liver, thereby reducing gluconeogenesis and enhancing insulin sensitivity [23]. Here, PRKAB1 is linked to type 2 diabetes mellitus.